Novo Integrated Sciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Novo Integrated Sciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-30.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-30.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Recent updates

Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch

Jul 11

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

Apr 18

Novo Integrated Sciences prices 4M unit public offering at $.50/unit

Oct 14

Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue

Jul 11

Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Nov 23

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Aug 07

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Mar 02

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NVOS şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NVOS şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Novo Integrated Sciences Piyasaya Karşı Temettü Getirisi

NVOS temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NVOS)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Healthcare)	1.6%
Analist tahmini (NVOS) (3 yıla kadar)	n/a

Önemli Temettü: NVOS şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NVOS şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NVOS şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NVOS herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Novo Integrated Sciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) announces an Equity Buyback for $5 million worth of its shares.

Recent updates

Novo Integrated Sciences, Inc.(OTCPK:NVOS) dropped from S&P TMI Index

Novo Integrated Sciences, Inc.(OTCPK:NVOS) dropped from NASDAQ Composite Index

Novo Integrated Sciences, Inc., Annual General Meeting, Nov 22, 2024

Novo Integrated Sciences Intends to Request Hearing Before Nasdaq Hearing Panel

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) acquired Ophir Collection, Llc.

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.58 loss in 2Q 2023)

Novo Integrated Sciences, Inc. Announces Executive Changes

Novo Integrated Sciences, Inc. Receives A Notification Letter from the Nasdaq Stock Market, LLC

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Novo Integrated Sciences Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) announces an Equity Buyback for $5 million worth of its shares.

Novo Integrated Sciences, Inc.'s IoNovo for Kids receives Registration Number and Regulatory Approval by Turkey’s Ministry of Health

Novo Integrated Sciences, Inc.’ IoNovo Iodine Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health

Novo Integrated Sciences, Inc., Annual General Meeting, Sep 29, 2023

New minor risk - Revenue size

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.13 loss in 3Q 2022)

Novo Integrated Sciences, Inc. Appoints Vivek Sethi as Principal Financial Officer

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.067 loss in 1Q 2022)

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump

High number of new and inexperienced directors

Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences Announces Receipt of Notice from Nasdaq

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Novo Integrated Sciences Receives A Notification Letter from Nasdaq Regarding Minimum Bid Price Requirements

High number of new and inexperienced directors

Novo Integrated Sciences, Inc. has completed a Composite Units Offering in the amount of $2 million.

Novo Integrated Sciences, Inc. has completed a Composite Units Offering in the amount of $2 million.

Novo Integrated Sciences prices 4M unit public offering at $.50/unit

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.016 loss in 3Q 2021)

Novo Integrated Sciences, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2022

Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue

Novo Integrated Sciences, Inc., Annual General Meeting, Aug 19, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.056 loss in 2Q 2021)

Less than half of directors are independent

Novo Integrated Sciences, Inc. announced delayed 10-Q filing

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?

Novo Integrated Sciences, Inc. (NasdaqCM:NVOS) agreed to acquire Seven Pharmacies in the United States.

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.016 loss per share (vs US$0.004 loss in 3Q 2020)

Principal Financial Officer & Principal Accounting Officer Sterling Jimenez has left the company

Principal Financial Officer & Principal Accounting Officer has left the company

Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.022 loss in 2Q 2020)

Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?

Novo Integrated Sciences Announces Three New Independent Directors Appointments to Its Board of Directors and Formation of an Audit Committee

Novo Integrated Sciences, Inc. Announces Executive Changes

Novo Integrated Sciences, Inc. announced delayed annual 10-K filing

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin